Introduction

Arthrosamid injections are an exciting new option for treating knee osteoarthritis, offering a less invasive alternative to surgery. These injections use a special polyacrylamide hydrogel to improve joint function and ease pain. For many people in the UK, one big question is whether private health insurance covers this treatment and how to manage the costs involved. In this article, we’ll explain the current insurance stance on Arthrosamid, why it’s often excluded, and practical ways to pay for it. Our goal is to provide clear, helpful advice so you can make informed decisions about your treatment.

Current Insurance Policies: Where Do Arthrosamid Injections Stand?

Private health insurers in the UK tend to be cautious about new treatments. At the moment, most insurers do not cover Arthrosamid injections. This is because Arthrosamid is relatively new, and insurers usually wait for plenty of solid long-term evidence and official guidelines before agreeing to cover such therapies.

Arthrosamid has been approved for use and is gaining traction in clinics. As noted by Cole and colleagues (2022), “this PAAG hydrogel seems to be an efficacious and safe treatment option for knee OA and provides positive results for at least 2 years.” However, most insurers want even longer-term proof before changing their policies. Some minor schemes may offer limited coverage, but for the vast majority, self-funding remains necessary.

Why Insurers May Exclude Arthrosamid Injections

When deciding which treatments to cover, insurers consider safety, approval status, and whether the benefit justifies the cost. Arthrosamid injections are often excluded for several reasons:

• Limited Long-Term Evidence: Although studies show good results up to two years, insurers typically want longer follow-up data. Research reports “statistically significant data at 52 weeks and 13 months,” supporting effectiveness at one year (Cole et al., 2022).
• Lack of NICE Guidance: The National Institute for Health and Care Excellence (NICE) has yet to recommend Arthrosamid specifically.
• Cost vs. Benefit: Insurers carefully weigh treatment costs against expected benefits across their members, often favouring well-established options.

This cautious approach is common with new treatments. Established knee injections, like corticosteroids or hyaluronic acid, are more often covered thanks to their longer history and reliable data. Interestingly, one study found “numerically superior data compared to hyaluronic acid” for Arthrosamid (Cole et al., 2022), but this hasn’t yet changed insurer policies.

A recent study also confirmed that Arthrosamid “offers comparable short-term efficacy and modest advantage at 6 months, but limited long-term superiority” (Aykaç et al., 2025). This helps explain why insurers remain cautious—they want clear evidence it works well over the long haul.

On the safety front, reassuringly, laboratory tests showed “no statistically significant effects on cell survival or neurotoxicity” when the hydrogel was tested in human nerve cells (Walmod et al., 2025), supporting its safety profile.

Self-Funding Explained: What to Expect When Paying Out-of-Pocket

If private insurance doesn’t cover Arthrosamid, self-funding is the alternative. This means you pay directly for all consultations, injections, and follow-up care.

In the UK, Arthrosamid injections typically cost between £1,000 and £2,000 per treatment session, varying by clinic and which services are included like imaging or aftercare. Many clinics offer payment plans such as monthly instalments or healthcare loans to help spread the cost.

Your treatment journey will start with an initial consultation to assess whether Arthrosamid suits you, followed by the injection itself. Aftercare appointments help monitor progress. When considering self-pay, make sure to ask clinics for a clear breakdown of all fees and check what payment options they offer to avoid surprises.

Other Ways to Manage Treatment Costs and Navigating Patient Pathways

There are several ways to reduce the financial impact of Arthrosamid injections:

• Package Deals and Off-Peak Discounts: Some clinics offer bundles or lower prices during quieter times.
• Appealing to Your Insurer: If you have private health insurance, it’s worth asking if coverage can be reconsidered. Supporting your appeal with medical reports and letters from your specialist can make a difference.
• Alternative Funding: You might explore options like healthcare allowances from your employer, medical credit schemes, or charitably funded grants.

For those insured, persistence and clear communication with insurers can sometimes help unlock support. If uninsured, look for clinics with flexible payment plans. Above all, keep open communication with your provider and insurer. Educating yourself about costs, coverage, and funding routes will help you take confident steps toward treatment.

Conclusion

To sum up, most private health insurance providers in the UK currently do not cover Arthrosamid injections due to limited long-term data and regulatory guidance. As a result, many patients need to pay for treatment themselves, though flexible finance options are often available. Encouragingly, research shows Arthrosamid is safe and effective for at least two years, with no reported neurotoxic effects (Cole et al., 2022; Walmod et al., 2025). That said, longer-term advantages remain uncertain (Aykaç et al., 2025), which explains insurers’ hesitancy.

If you’re considering Arthrosamid, staying informed and proactive is essential. Discuss payment options with clinics, consider appealing to your insurer, and explore all possible funding sources. With the right information and support, managing the financial side of your knee osteoarthritis treatment can become a more manageable experience.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine. https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina‐Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430